Involvement of T2677T multidrug resistance gene polymorphism in Interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients

摘要

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the progressive accumulation of phenotypically mature malignant lymphocytes [1]. B-CLL therapy remains unsatisfactory due to repeated resurgences of the chemoresistant disease. Chemore-sistance remains a major therapeutic challenge in B-CLL. The precise mechanism underlying chemore-sistance in B-CLL is not clear, but one of the main contributors is thought to be a dysregulation of apop-tosis, and an overexpression of antiapoptotic molecules, such as cytokines [2]. B-CLL cells commonly express several transporter proteins involved in multidrug resistance including P-glycoprotein (P-gp, also known as MDR1 and ABCB1), multidrug resistance-associated protein-1 (MRP1, ABCC1) and lung resistance protein (LRP) [3]. A relatively high level of P-gp expression, the classical mechanism of multidrug resistance, appears to be an intrinsic feature of B-CLL tumor cells [3].